Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
38.49
+0.05 (0.13%)
Dec 24, 2025, 1:00 PM EST - Market closed
HRMY Stock Forecast
Stock Price Forecast
The 9 analysts that cover HRMY stock have a consensus rating of "Strong Buy" and an average price target of $51.33, which forecasts a 33.36% increase in the stock price over the next year. The lowest target is $36 and the highest is $70.
Price Target: $51.33 (+33.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HRMY stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $39 → $46 | Buy | Maintains | $39 → $46 | +19.51% | Dec 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +42.89% | Nov 24, 2025 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +9.12% | Nov 24, 2025 |
| Mizuho | Mizuho | Buy Maintains $36 → $39 | Buy | Maintains | $36 → $39 | +1.33% | Nov 6, 2025 |
| UBS | UBS | Strong Buy Maintains $50 → $43 | Strong Buy | Maintains | $50 → $43 | +11.72% | Oct 15, 2025 |
Financial Forecast
Revenue This Year
879.91M
from 714.73M
Increased by 23.11%
Revenue Next Year
1.02B
from 879.91M
Increased by 16.15%
EPS This Year
3.26
from 2.51
Increased by 29.83%
EPS Next Year
4.23
from 3.26
Increased by 29.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 910.4M | 1.1B | ||||
| Avg | 879.9M | 1.0B | ||||
| Low | 839.2M | 946.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27.4% | 25.2% | ||||
| Avg | 23.1% | 16.1% | ||||
| Low | 17.4% | 7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.70 | 5.61 | |||
| Avg | 3.26 | 4.23 | |||
| Low | 2.86 | 3.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.3% | 72.1% | |||
| Avg | 29.8% | 29.7% | |||
| Low | 14.0% | -5.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.